UNSPSC 51202402: Basiliximab

This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6378H9844N1698O1997S48, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9927MT646M, more generally known as basiliximab. European Medicines Agency schedules basiliximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12468MIG. The term BASILIXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 11, No. 3 1997, list 38.

UNSPSC 51202402 Basiliximab, a Commodity code, does not match the work actually being solicited under this code in recent state and local opportunities. The four recent solicitations on file—a Seminole County naloxone and drug deactivation systems IFB, a Texas HHS direct-to-manufacturer prescriptions RFI, a Tampa Fire Department medical and first aid supplies IFB, and an MMCAP generic pharmaceuticals and OTC products RFP—involve procurement of emergency response medical supplies, community health products, pharmacy benefit management capabilities, and generic drug distribution. None of these represent basiliximab (an immunosuppressant monoclonal antibody used in transplant rejection prevention), and the code shows little relevant recent activity aligned with its nominal scope. The disconnect suggests either a data classification error or that basiliximab is rarely or not currently procured by state and local government bodies through these tracked channels.

State and local procurement bodies—counties, cities, fire departments, health and human services agencies, and multistate cooperative purchasing alliances—are actively soliciting medical consumables, emergency response supplies, pharmaceutical distribution, and pharmacy benefit services across Florida, Texas, Minnesota, and Oregon. The Tampa procurement (Bid 26-P-00145, due March 13, 2026) targeted certified small local business enterprises with a 5% discount; the MMCAP RFP (due March 26, 2026) engaged manufacturers on generic drugs and OTC products through three authorized wholesalers; and Seminole County's IFB (due July 26, 2023) sought quarterly deliveries of naloxone and drug deactivation systems. Until the code begins capturing basiliximab or closely related pharmaceutical products in state and local bid activity, pursuit under this Commodity code is not supported by current market signals.